These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 37505446)

  • 1. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
    Gisbert JP; Chaparro M
    Drugs; 2023 Sep; 83(13):1179-1205. PubMed ID: 37505446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.
    Mañosa M; Fernández-Clotet A; Nos P; Martín-Arranz MD; Manceñido N; Carbajo A; Hinojosa E; Hernández-Camba A; Muñoz-Pérez R; Boscá-Watts M; Calvo M; Sierra-Ausín M; Sánchez-Rodríguez E; Barreiro-de Acosta M; Núñez-Alonso A; Zabana Y; Márquez L; Gisbert JP; Guardiola J; Sáinz E; Delgado-Guillena P; Busquets D; van Domselaar M; Girona E; Lorente R; Casas-Deza D; Huguet JM; Maestro S; Cabello MJ; Castro J; Iborra M; Cañete F; Calafat M; Domènech E;
    Dig Liver Dis; 2023 Jan; 55(1):46-52. PubMed ID: 35948459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
    Holko P; Kawalec P; Pilc A
    Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.
    Cañete F; Mañosa M; Casanova MJ; González-Sueyro RC; Barrio J; Bermejo F; Nos P; Iglesias-Flores E; García-Planella E; Pérez-Calle JL; Vicente R; Vera M; Ramos L; Rivero M; De Francisco R; Montserrat A; Benítez O; Navarro P; Taxonera C; Hinojosa E; Márquez-Mosquera L; Navarro-Llavat M; Ramírez-de la Piscina P; Gomollón F; Rodríguez-Alonso L; Núñez-Alonso A; Fernández-Salazar L; Almela P; Ríos León R; De Castro L; Gisbert JP; Ricart E; Cabré E; Domènech E;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1862-1870. PubMed ID: 31006801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.
    Buisson A; Nancey S; Manlay L; Rubin DT; Hebuterne X; Pariente B; Fumery M; Laharie D; Roblin X; Bommelaer G; Pereira B; Peyrin-Biroulet L; Vuitton L;
    United European Gastroenterol J; 2021 Jun; 9(5):552-560. PubMed ID: 33951350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.
    Axelrad JE; Li T; Bachour SP; Nakamura TI; Shah R; Sachs MC; Chang S; Hudesman DP; Holubar SD; Lightner AL; Barnes EL; Cohen BL; Rieder F; Esen E; Remzi F; Regueiro M; Click B
    Inflamm Bowel Dis; 2023 Jun; 29(6):888-897. PubMed ID: 35905032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
    Yamada A; Komaki Y; Patel N; Komaki F; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
    Inflamm Bowel Dis; 2018 Feb; 24(3):502-509. PubMed ID: 29462385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of post-operative recurrence of Crohn's disease among patients with prior anti-TNFα failure: A retrospective multicenter study.
    Le Cosquer G; Altwegg R; Rivière P; Bournet B; Boivineau L; Poullenot F; Bozon A; Buscail L; Laharie D; Gilletta C
    Dig Liver Dis; 2023 Jun; 55(6):727-734. PubMed ID: 36192340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
    García MJ; Rivero M; Fernández-Clotet A; de Francisco R; Sicilia B; Mesonero F; de Castro ML; Casanova MJ; Bertoletti F; García-Alonso FJ; López-García A; Vicente R; Calvet X; Barreiro-de Acosta M; Ferrer Rosique J; Varela Trastoy P; Nuñez A; Ricart E; Riestra S; Arias García L; Rodríguez M; Arranz L; Pajares R; Mena R; Calafat M; Camo P; Bermejo F; Ponferrada Á; Madrigal RE; Llaó J; Sesé E; Sánchez E; Pineda Mariño JR; González Muñoza C; Carbajo López AY; Julián AB; Villoria Ferrer A; Baston-Rey I; Jara L; Almela P; Codesido L; de la Maza S; Leal C; Caballol B; Pérez-Martínez I; Vinuesa Campo R; Crespo J; Domènech E; Chaparro M; Gisbert JP
    J Crohns Colitis; 2024 Jan; 18(1):65-74. PubMed ID: 37522878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
    Yanai H; Kagramanova A; Knyazev O; Sabino J; Haenen S; Mantzaris GJ; Mountaki K; Armuzzi A; Pugliese D; Furfaro F; Fiorino G; Drobne D; Kurent T; Yassin S; Maharshak N; Castiglione F; de Sire R; Nardone OM; Farkas K; Molnar T; Krznaric Z; Brinar M; Chashkova E; Livne Margolin M; Kopylov U; Bezzio C; Bar-Gil Shitrit A; Lukas M; Chaparro M; Truyens M; Nancey S; Lobaton T; Gisbert JP; Saibeni S; Bacsúr P; Bossuyt P; Schulberg J; Hoentjen F; Viganò C; Palermo A; Torres J; Revés J; Karmiris K; Velegraki M; Savarino E; Markopoulos P; Tsironi E; Ellul P; Calviño Suárez C; Weisshof R; Ben-Hur D; Naftali T; Eriksson C; Koutroubakis IE; Foteinogiannopoulou K; Limdi JK; Liu E; Surís G; Calabrese E; Zorzi F; Filip R; Ribaldone DG; Snir Y; Goren I; Banai-Eran H; Broytman Y; Amir Barak H; Avni-Biron I; Ollech JE; Dotan I; Aharoni Golan M
    J Crohns Colitis; 2022 Dec; 16(12):1882-1892. PubMed ID: 35895074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
    Kassouri L; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Dig Liver Dis; 2020 Oct; 52(10):1148-1155. PubMed ID: 32828693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Parrot L; Dong C; Carbonnel F; Meyer A
    Aliment Pharmacol Ther; 2022 Feb; 55(4):380-388. PubMed ID: 34854100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti -TNFα agents in preventing the postoperative recurrence of Crohn's disease: Do they still play a role in the biological era?
    Liu C; Li N; Zhan S; Tian Z; Wu D; Li T; Zeng Z; Zhuang X
    Expert Opin Biol Ther; 2021 Nov; 21(11):1509-1524. PubMed ID: 34350811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Aliment Pharmacol Ther; 2020 May; 51(10):948-957. PubMed ID: 32249966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.